MeSH tree: C15.604.515.569.480.150.585
A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein cFLIP can be used to override the defenses of Diffuse Large B Cell Lymphoma (DLBCL) against programmed ...
7 hours ago
0
2
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B-cell lymphoma patients than the widely used International Prognostic Index. By identifying patients ...
Apr 22, 2026
0
1
A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) has uncovered a crucial biological "off switch" in diffuse large B cell lymphoma (DLBCL), the most ...
Apr 20, 2026
0
9
Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections and tumors. For these processes to function properly, immune cells (B cells and T cells) must be ...
Mar 25, 2026
0
4
Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a combination of four chemotherapy ...
Mar 25, 2026
0
6
An innovative platform developed by PKU researchers called "cf-EpiTracing" has proved capable of detecting and tracing diseases from as little as 50 μl of human plasma, or roughly a drop of blood. The research, published ...
Mar 16, 2026
0
11
A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 in the journal Cell, by ...
Mar 6, 2026
0
16
A new UNC study finds that a chemical derived from ashwagandha disrupts viral and cancer processes that make B-cell lymphomas difficult to treat with standard chemotherapy. Cancer has many causes, including inherited genes, ...
Feb 19, 2026
0
15
Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive ...
Feb 9, 2026
0
7
A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved for treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, ...
Feb 5, 2026
0
8
